drugset / Trial / NCT02087540

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

NCT02087540

Phase 3 Unknown 310 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.

Timeline

Start
2013-05
Primary completion
2014-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral